Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1951 3
1952 14
1953 10
1954 7
1955 9
1956 10
1957 8
1958 10
1959 5
1964 3
1966 1
1970 2
1971 10
1972 13
1973 9
1974 23
1975 18
1976 8
1977 9
1978 8
1979 10
1980 10
1981 10
1982 12
1983 6
1984 12
1985 7
1986 13
1987 17
1988 8
1989 15
1990 23
1991 23
1992 11
1993 11
1994 19
1995 18
1996 24
1997 12
1998 31
1999 29
2000 20
2001 24
2002 24
2003 25
2004 17
2005 23
2006 36
2007 24
2008 52
2009 54
2010 47
2011 40
2012 37
2013 40
2014 35
2015 40
2016 52
2017 46
2018 61
2019 42
2020 45
2021 43
2022 53
2023 41
2024 17

Text availability

Article attribute

Article type

Publication date

Search Results

1,312 results

Results by year

Filters applied: . Clear all
Page 1
Carcinogenic risk in patients treated with UVA-1 phototherapy: A 5-year retrospective study.
Cosetti D, Cioppa V, Rubegni P, Trovato E. Cosetti D, et al. Photodermatol Photoimmunol Photomed. 2024 May;40(3):e12975. doi: 10.1111/phpp.12975. Photodermatol Photoimmunol Photomed. 2024. PMID: 38787937
All enrolled patients underwent an oncologic prevention visit annually with a 5-year follow-up with clinical evaluation of the entire skin surface. RESULTS: During the 5-year follow-up, we recorded a case of basal cell carcinoma (BCC) in the cervical region and one case of …
All enrolled patients underwent an oncologic prevention visit annually with a 5-year follow-up with clinical evaluation of the entire …
S2k guideline: Diagnosis and therapy of localized scleroderma.
Kreuter A, Moinzadeh P, Kinberger M, Horneff G, Worm M, Werner RN, Hammacher A, Krieg T, Wenzel J, Oeschger M, Weibel L, Müllegger R, Hunzelmann N. Kreuter A, et al. J Dtsch Dermatol Ges. 2024 Apr;22(4):605-620. doi: 10.1111/ddg.15328. Epub 2024 Mar 1. J Dtsch Dermatol Ges. 2024. PMID: 38426689
The updated S2k guideline deals with the diagnosis and therapy of localized scleroderma (LoS). LoS represents a spectrum of sclerotic skin diseases in which, depending on the subtype and localisation, structures such as adipose tissue, muscles, joints, and bones may …
The updated S2k guideline deals with the diagnosis and therapy of localized scleroderma (LoS). LoS represents a spectrum of sc …
Juvenile eosinophilic fasciitis: a single center case series.
Stubbs LA, Ogunbona O, Beil E, Szafron V, Adesina A, Anvari S, Lai J, Ramirez A, Ditzler MG, DeGuzman M. Stubbs LA, et al. Pediatr Rheumatol Online J. 2024 Feb 24;22(1):29. doi: 10.1186/s12969-024-00960-w. Pediatr Rheumatol Online J. 2024. PMID: 38395889 Free PMC article.
Inclusion criteria required patients to be under 18 years of age at the time of diagnosis and to have confirmed diagnosis through clinical history, imaging, and histology. RESULTS: Most of our cohort were female (83%) and non-Hispanic white (50%). ...Follow-up periods rang …
Inclusion criteria required patients to be under 18 years of age at the time of diagnosis and to have confirmed diagnosis through clinica
Nintedanib in systemic sclerosis treatment: a case report.
Kudsi M, Tarcha R, Khalayli N. Kudsi M, et al. J Med Case Rep. 2024 Feb 23;18(1):110. doi: 10.1186/s13256-024-04433-2. J Med Case Rep. 2024. PMID: 38388392 Free PMC article.
BACKGROUND: Nintedanib was approved for the treatment of scleroderma and scleroderma-related interstitial lung disease, as it decrease the forced expiratory volume. ...The optimal antihypertensive agent for scleroderma renal crisis is an ACE inhibitor. The ma …
BACKGROUND: Nintedanib was approved for the treatment of scleroderma and scleroderma-related interstitial lung disease, as it …
[Localized scleroderma].
Al-Gburi S, Kreuter A, Moinzadeh P. Al-Gburi S, et al. Dermatologie (Heidelb). 2024 Mar;75(3):197-207. doi: 10.1007/s00105-024-05297-9. Epub 2024 Feb 16. Dermatologie (Heidelb). 2024. PMID: 38363312 Review. German.
Localized scleroderma (LS), also called circumscribed scleroderma or morphea, comprises a heterogeneous group of diseases that can be classified into four subtypes: limited, linear, generalized, and mixed LS. ...A distinction is made between forms that primar
Localized scleroderma (LS), also called circumscribed scleroderma or morphea, comprises a heterogeneous group of diseas
Clinical, Histologic, and Transcriptomic Evaluation of Sequential Fat Grafting for Morphea: A Nonrandomized Controlled Trial.
Liu J, Wang J, Zhang Q, Lu F, Cai J. Liu J, et al. JAMA Dermatol. 2024 Apr 1;160(4):425-433. doi: 10.1001/jamadermatol.2023.5908. JAMA Dermatol. 2024. PMID: 38324287 Clinical Trial.
MAIN OUTCOME AND MEASURES: The primary outcome included changes in the modified Localized Scleroderma Skin Severity Index (mLoSSI) and Localized Scleroderma Skin Damage Index (LoSDI) scores as evaluated by 2 independent blinded dermatologists. ...Histo …
MAIN OUTCOME AND MEASURES: The primary outcome included changes in the modified Localized Scleroderma Skin Severity Index (mLo …
Novel multispectral imaging to predict disease progression in pediatric morphea.
O'Connor C, McCarthy S, Kiely L, McAuliffe MAP, Bennett M. O'Connor C, et al. Pediatr Dermatol. 2024 Mar-Apr;41(2):229-233. doi: 10.1111/pde.15485. Epub 2024 Feb 2. Pediatr Dermatol. 2024. PMID: 38305508
BACKGROUND: Morphea, or localized scleroderma, is an inflammatory, fibrosing skin disorder that can be progressive and debilitating. ...Multispectral images of affected and matched contralateral unaffected sites were obtained using the Antera 3D camera. Clinical
BACKGROUND: Morphea, or localized scleroderma, is an inflammatory, fibrosing skin disorder that can be progressive and debilit …
Perspective to precision medicine in scleroderma.
Komura K, Yanaba K, Bouaziz JD, Yoshizaki A, Hasegawa M, Varga J, Takehara K, Matsushita T. Komura K, et al. Front Immunol. 2024 Jan 18;14:1298665. doi: 10.3389/fimmu.2023.1298665. eCollection 2023. Front Immunol. 2024. PMID: 38304250 Free PMC article.
However, such an analysis should also lead to improvements in the design of appropriately stratified clinical trials to determine the effects and prediction of targeted therapies. An approach based on drug response preclinically conducted using patients' own fibroblasts in …
However, such an analysis should also lead to improvements in the design of appropriately stratified clinical trials to determine the …
Development of Morphea Following Treatment with an ADA Biosimilar: A Case Report.
Venetsanopoulou AI, Mavridou K, Pelechas E, Voulgari PV, Drosos AA. Venetsanopoulou AI, et al. Curr Rheumatol Rev. 2024;20(4):451-454. doi: 10.2174/0115733971266803231117072453. Curr Rheumatol Rev. 2024. PMID: 38243962
However, the use of TNFi has been associated with the development of many autoimmune phenomena and paradoxical skin manifestations that may present as the same type of clinical indications for which the TNFi effectively used. Thus, they may display as arthritis, uveitis, c …
However, the use of TNFi has been associated with the development of many autoimmune phenomena and paradoxical skin manifestations that may …
1,312 results